GlassScriptPhysician profile
Lauren Halvorson
NPI 1871818328
$3,275.70
in general payments reported to CMS, 2019-2025
26 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $48.06 · 2021: $183 · 2022: $209 · 2023: $636 · 2024: $932 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,688 · Education: $15.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,688.34 |
| Education | $15.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $717.15 | 2022-2025 | |
| Pfizer INC. | $287.11 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $240.49 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $224.66 | 2023-2025 | |
| Janssen Biotech, INC. | $216.01 | 2021-2025 | Stelara, Tremfya, Simponi |
| Regeneron Healthcare Solutions, INC. | $201.29 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $199.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $193.57 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.05 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Ironwood Pharmaceuticals, INC | $170.89 | 2019-2023 | Linzess |
| Gilead Sciences, INC. | $93.92 | 2023-2025 | |
| Celltrion USA INC. | $77.90 | 2024-2025 | Zymfentra, Vegzelma |
| Braintree Laboratories, INC. | $59.85 | 2020-2023 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $56.56 | 2025 | Iqirvo |
| Lilly USA, LLC | $55.30 | 2024-2025 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $51.75 | 2019-2023 | Ocaliva |
| Fujifilm Healthcare Americas Corporation | $45.99 | 2024 | Fujifilm |
| Redhill Biopharma INC. | $38.99 | 2021-2022 | |
| Qol Medical, LLC | $32.00 | 2025 | Sucraid |
| Ardelyx, INC. | $23.74 | 2024 | Ibsrela |
| Novo Nordisk INC | $22.57 | 2025 | Wegovy |
| Allergan, INC. | $22.32 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $17.86 | 2022 | |
| Merck Sharp & Dohme LLC | $16.24 | 2023 | Zinplava, Dificid |
| Phathom Pharmaceuticals, INC. | $14.06 | 2024 | Voquezna |
| Capsovision, INC. | $13.49 | 2024 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Halvorson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.